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Gabapentin Supplemented With Ropivacain Block
of Trigger Points Improves Pain Control and Quality of Life
in Trigeminal Neuralgia Patients When Compared
With Gabapentin Alone
Laurinda Lemos, MD,*w Sara Flores,w Pedro Oliveira, PhD,z and Armando Almeida, PhD*
Objective: Pain control in trigeminal neuralgia (TN) is achieved
using anticonvulsivants, mainly carbamazepine. When this drug
cannot be used, other drugs like gabapentin (GBP) have
been used to provide adequate pain control. To improve the
therapeutic eﬀect of GBP, we evaluated the clinical eﬃcacy of
associating GBP with ropivacain (ROP) analgesic block of facial
trigger points in TN patients.
Design: Thirty-six TN patients were randomly assigned during 4
weeks to 1 of the following protocols: Protocol I—daily oral
GBP administered in a titrated dose; Protocol II—ROP applied
as analgesic block to TN trigger points once a week; Protocol
III—daily oral GBP plus ROP once a week. Protocol II had to
be discontinued in 7/12 patients owing to insuﬃcient pain
control. Pain intensity was evaluated by the Visual Analog Scale
(VAS) and disability was assessed by Sickness Impact Proﬁle.
Results: When compared with Protocol I, Protocol III
(GBP+ROP) patients showed (1) a reduction of VAS score
after 7 and 28 days of treatment, an eﬀect that was still present
6 and 12 months later; (2) a faster reduction of VAS score using
a signiﬁcantly lower dose of GBP; (3) a smaller total and daily
GBP dose at the end of the treatment, which resulted in a total
absence of adverse side eﬀects; and (4) an improvement of the
functional well-being measured by the Sickness Impact Proﬁle.
The number needed to treat (NNT) (GBP+ROP vs. GBP
protocols) to obtain 1 GBP+ROP-treated patient with at least
50% pain relief was 1.71 (day 7) and 2.40 (day 28).
Conclusions: The association of GBP and ROP is safe, without
side eﬀects and results in an important clinical beneﬁt associated
to an improvement of the functional health status of TN
patients when compared with GBP alone. This may constitute
a therapeutic alternative for pain control in TN patients who
cannot be treated with carbamazepine.
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Trigeminal neuralgia (TN) has a strong clinical impactbecause its severe and unpredictable pain periods
induce important functional and psychoaﬀective changes
in patients.1 Pain is described as burning or shooting
and, is characterized by paroxysmal ‘‘electric shocklike’’
intense episodes, with an instantaneous progression from
the onset to the peak. Pain lasts from several seconds to
less than 2 minutes and is triggered by a non-noxious
stimulus, usually when eating, speaking, or touching on
the naso-labial fold or perioral region (trigger points).2
Treatment options can include a variety of drug thera-
pies, but progressively more invasive techniques may
be needed.3
TN does not respond to primary analgesics and the
solution is the use of adjuvant analgesics, mainly anti-
convulsivants (ACs). Several ACs are known to stabilize
plasma membrane of peripheral nerve ﬁbers by inhibiting
ectopic discharges in altered membranes.4 Carbamazepine
(CBZ) has been the most eﬃcacious (beneﬁcial in 70% of
patients) and most used AC in the treatment of TN1 and
was the only drug evaluated in large placebo-controlled
trials.1,5 However, the main problem concerning the use
of ACs is the tolerance to the drug doses controlling
pain, owing to side eﬀects (dizziness, somnolence, and
ataxias).4,6 The absence of CBZ eﬃcacy in some patients,
cases of intolerance,7 hypersensitivity, ﬂuid retention,8
drug interactions, a narrower therapeutic index and a
higher degree of adverse side eﬀects than recent drugs like
gabapentin (GBP) has led to a progressively increased use
of the latter drug in several neuropathic pain syn-
dromes.9–12 GBP has been used alone13 or in association
with CBZ or iamotrigine14 and results in pain reduction
in at least 47% of TN patients. However, it should be
noted that the eﬀectiveness of GBP and other drugs likeCopyright r 2007 by Lippincott Williams & Wilkins
Received for publication April 16, 2007; accepted August 8, 2007.
From the *Health and Life Sciences Research Institute (ICVS), School
of Health Sciences; zProduction and Systems Engineering,
University of Minho, Braga; and wHospital Center of Alto Ave,
Unit of Fafe, Fafe, Portugal.
Supported by Fundac¸a˜o para a Cieˆncia e Tecnologia (FCT) Project no
POCTI/NSE/46399/2002, FEDER and Fundac¸a˜o Calouste Gulben-
kian Project no. 74551.
Reprints: Prof Armando Almeida, PhD, Health and Life Sciences
Research Institute, School of Health Sciences, University of Minho,
Campus de Gualtar, 4710-057 Braga, Portugal (e-mail: aalmeida@
ecsaude.uminho.pt).
ORIGINAL ARTICLE
Clin J Pain  Volume 00, Number 00, ’’ 2007 1
phenytoin and topiramate in TN have not been evaluated
in large scale trials,1 probably because of the relatively
rarity of this pathology.
Surprisingly, although the association of analgesics
with diﬀerent mechanisms of action may putatively result
in analgesia potentiation and less adverse side eﬀects,
the possibility for associating drug therapies has been
explored very little until present.4 To the best of our
knowledge, and excluding the association of diﬀerent
ACs,14 no treatment associating diﬀerent drug classes
have been described and no multimodal prospective trials
have been performed for TN. A potential adjunctive
treatment that have not been explored, is the combination
of an AC with an analgesic block of TN facial trigger
points using a local anesthetic. These drugs have a
complementary mechanism of action because local
anesthetics at low doses block anomalous membrane
excitability and ACs block also ectopic activity of
peripheral ﬁbers without abolishing sensory transmis-
sion.15 Thus, their association may have improved control
over the instability of membrane potential and thus
reinforce the clinical improvement of TN patients.
The objective of the present study was to improve
the clinical eﬀect of GBP as an alternative protocol to
CBZ, whenever this drug cannot be the ﬁrst choice
treatment. We evaluated the therapeutic eﬃcacy of
associating the oral administration of GBP with ropiva-
cain (ROP) local analgesia of TN trigger points, in
comparison with GBP monotherapy.13 We selected the
local anesthetic ROP which has a lower risk of
cardiovascular and nervous toxicity and a higher aﬃnity
for Ad-nociceptive and C-nociceptive ﬁbers than Ab-
innocuous ﬁbers when compared with bupivacain.16
Additionally, ROP has a smaller risk in case of
continuous or successive bolus administration than
levobupivacain. The outcomes analyzed were (1) the
degree of pain reduction, (2) the number of daily
paroxysmal pain crises, (3) the time necessary to obtain
satisfactory clinical results, (4) the degree of adverse side
eﬀects, and (5) the impact upon Quality of Life. Part of
this study has been presented in abstract form.17
METHODS
The organization of the present study followed as
possible the recommendations for improving the quality
of reports of parallel-group randomized trials.18
Patients—Entry and Exclusion Criteria
Participants for this study were recruited from the
Chronic Pain Unit of the Hospital Center of Alto Ave,
Portugal during the years 2003 to 2006. Patients were
eligible for the study if they had a pain intensity Visual
Analog Scale (VAS) score (see below) Z6 and met the
consensus criteria for the diagnosis of primary (idio-
pathic) TN.8 The inclusion criteria were:
 Occurrence of episodes of intense facial paroxysmal
pain in territory innervated by the trigeminal nerve
(VAS score Z6)
 Presence of a normal neurologic examination
 Normal neuroimaging analysis
The following exclusion criteria were also considered:
 Patient refuse to participate
 Psychologic instability
 Atypical pain location (eg, no speciﬁc trigger points)
 Anticlotting therapy
 Secondary TN2
* Multiple sclerosis
* Temporomandibular joint disorders
* Neoplasias
 Altered neurologic proﬁle
* Hypoesthesia
* Dysesthesia
* Anesthesia
* Paresis
 Association with other cranial nerve neuralgias
(eg, glossopharyngeal neuralgia)
 Imagiologic alterations
 Proposed surgical intervention
* Compression of the Gasser ganglion
* Preference of the patient
The treatment protocols used were accepted by the
Hospital Ethical Committee and the patients were
informed that (1) they would be submitted to 1 of 3
diﬀerent protocols to solve their pain problem and
(2) they could drop or change treatment if no pain
control was achieved. All patients signed an informed
consent.
Random Allocation
It has been recommended that a detailed description
of the expanded criteria followed for adequate allocation
of patients to treatment groups should prevail over
minimal description.19 The 36 TN patients deﬁned to
enter the study were the ﬁrst 36 arriving to the chronic
Pain Unit and fulﬁlling the inclusion criteria (Table 1;
Fig. 1). The ﬁrst patient was presented at the entrance of
the study with a box containing 36 sealed code opaque
envelops, where the treatment protocol to be followed
was speciﬁed (12 envelops for each protocol, which was
written in a cardboard inside) [method adapted from the
unrestricted (simple) randomization described by Doig
and Simpson20]. The random attribution of an envelope
to the patient ended when he/she takes 1 from the box
without looking inside. The second patient fulﬁlling the
entry criteria to the study was presented to the box with
the 35 envelopes left, which were mixed before the second
patient took an envelope. The same sequence was
followed to preserve the random allocation of the 34
other patients to the 34 envelopes left.
Treatment Protocols
Patients were allocated to one of the following
treatment protocols (Fig. 1):
Protocol I
Protocol I—treatment using only GBP,13 which was
administered orally in progressively higher doses.16 The
ﬁrst 2 days, patients were given 100mg/d oral GBP at
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night by prescription from the hospital staﬀ; from the
third to the seventh day, they progressively received from
100 to 300mg/d oral GBP to decrease pain intensity (until
VAS <6; see below VAS deﬁnition). From the seventh
day to the end of the study (28th day), the dose taken by
each patient could amount to 300 to 900mg/d oral GBP if
the pain intensity reached a VAS score Z6 (see below).
Each 7 days, during their visit to the Pain Unit, patients
were evaluated, the VAS score was recorded, and GBP
titration was veriﬁed. Patients were told that each
increase in GBP daily dose should be restricted to
100mg/d and taken when they felt worse. It is the
experience of our Pain Unit that all TN patients with
VAS scores of 9 to 10 felt much better and relieved when
their VAS score dropped below 6. Because patients
express their pain experience in this scale, the motiva-
tional-aﬀective impact of being free from their excruciat-
ing pain made them feel well and helped them cope with
some pain with all spectrum values of VAS scale below 6.
Thus, we deﬁned the VAS value of 6 as the threshold for
increasing drug therapy. In practice, however, patients
were free to increase their GBP dose by 100mg/d
whenever they felt the necessity for improving their pain
control.
Protocol II
Protocol II—administration of a superﬁcial anal-
gesic block with ROP to the trigger point(s) inducing
paroxysmal pain crises in TN patients. The injection was
performed at the Pain Unit under sterile conditions, using
a 27-gauge needle for administering subcutaneously
2mL21 of a 2mg/mL ROP solution in each trigger point
(Fig. 2). Each local block was performed once a week22
during the 1-month treatment (days 0, 7, 14, 21, and 28).
Patient usually reported immediate pain relief.
Protocol III
Protocol III—treatment using GBP plus ROP
(GBP+ROP). The GBP and ROP were administered
following the same rationale as for Protocols I and II,
respectively. Thus, at day 0, a ROP analgesic block was
performed on trigger points and 100mg of GBP
administered at night to each patient. On subsequent
days, the increase in GBP daily administration followed
the rationale described above for Protocol I and, each 7
days (days 7, 14, 21, and 28), a ROP block was performed
as for Protocol II.
During the 28-day treatment, all patients were
evaluated by the hospital staﬀ at the ﬁrst 2 days and
periodically at days 7, 14, 21, and 28. During the periods
between days 3 and 6, 8 and 13, 15 and 20, and 22 and 27,
patients were at home and were requested to record their
VAS pain intensity score in an individual Pain Diary
provided by the hospital staﬀ, the GBP dose (patients
from Protocols I and III), and the hour when medication
was taken.
Paracetamol 1000mg was used in this study for
breakthrough pain in those cases where patients needed
pain control between GBP doses, or if the study
medication was not having an analgesic eﬀect. They were
instructed to take it as needed every 8 hours with a
maximum of 4000mg/d. Patients were requested to keep a
calendar of time and amount of rescue medication used.
After the 1-month period of protocol treatment,
patients were requested to continue their treatment at
home, using the same GBP dose used at day 28 (Protocols
I and III). If Protocol II patients experienced a new pain
episode they were instructed to return to the Pain Unit for
evaluation and were provided the most adequate conven-
tional treatment.
Experimental Sequence and Primary
Outcome Measures
The application of each protocol treatment (Fig. 1)
was performed by a ﬁrst researcher (Experimenter 1;
Dr Laurinda Lemos), who was blinded to the VAS scores
of pain intensity and Sickness Impact Proﬁle (SIP) scores
of Quality of Life obtained by each patient. VAS and
SIP before and along the 28 days of protocol treatment
were evaluated by a second researcher (Experimenter 2;
Dr Sara Flores), who was blinded to the protocol assigned
to each patient. The statistical evaluation of the data
was performed by a third researcher (Experimenter 3;
Dr Pedro Oliveira). The mechanical procedures of mixing
the envelopes for their random allocation were performed
by a fourth person not belonging to the research staﬀ of
this study.
The predeﬁned primary outcome measures were:
(1) Evaluation of pain intensity using the VAS.23,24
Patients located their relative pain in a line marked
in each extremity with 0 (0: no pain—on the left) and
TABLE 1. Baseline Characteristics of the Patients
Protocol I
(GBP) (n=12)
Protocol II
(ROP)
(n=12*)
Protocol III
(GBP+ROP)
(n=12) P**
Age (y, average
and SD)
61 (10.8) 62 (7.7) 64 (19.2) 0.35
Sex (women/
total)
5/12 6/12 9/12 0.23
Pain location (trigeminal branches)
V1 or V2 or
V3
2 4 3
V1+V2 or
V2+V3
7 6 8
V1+V2+V3 3 2 1
Facial side
(right/total)
8/12 7/12 9/12
Type of pain
(electric
shock)
12 12 12
Pain duration at day 0
1-2 y 7 8 4
3-4 y 4 4 3
5 and more 1 0 5
*The 12 patients were included in the study on day 0 of the treatment, at days 7
and 30, only 5 patients showed adequate pain control.
**P values were obtained by Kruskal-Wallis test.
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10 (10: the worst pain imaginable—on the right).
Moderate pain was considered to be over 30mm
(VAS>3) and severe pain over 60mm (VASZ6).25
A pain reduction of 2 points in the VAS scale on the
100-mm VAS from the baseline pain score was
considered to be clinically signiﬁcant.26–28 Only VAS
scores evaluated at the beginning of the treatment
(day 0), the seventh day (day 7; just before ROP
administration), and at the end of the treatment
(day 28; 2 d after the last ROP administration) were
used for statistical comparison between protocols.
However, to increase GBP daily dose by 100mg,
the VAS score of the most intense pain period was
determined everyday by the patient at night and
recorded in the Pain Diary provided to each patient
by the hospital staﬀ.
(2) Daily number of paroxysmal pain episodes. This
variable was evaluated everyday, but only values
obtained at the end of the treatment period (day 28)
and 5 and 11 months after the end of the treatment
(follow-up) were used for statistical analysis. The
follow-up evaluation was performed at the end of
the day during a phone interview to each patient, who
was asked (1) how many pain attacks suﬀered during
that day or, in case of no pain, (2) how many pain
attacks suﬀered in the worst day of the last week
before interview. If no pain was felt during the last
week before interview, the staﬀ recorded 0 for the
patient.
(3) NNT. Instead of comparing a drug treatment with
a placebo group like the usual application of NNT
formula to clinical studies,29,30 we compare the
therapeutic result between a new proposed therapy
(GBP+ROP protocol) and a conventional treatment
(GBP protocol), as suggested by Altman.31 This
allows a comparison of eﬃcacy between the 2
clinical treatments.31 Thus, in the present study,
NNT is deﬁned as 1/[the proportion of patients
successfully treated with GBP+ROP (with at least
50% pain relief) the proportion of patients
successfully treated with the standard GBP
monotherapy], as expressed in the equation below.
The NNT of Protocol III over protocol I was
determined for days 7 and 28. The 95% conﬁdence
FIGURE 1. Consort flowchart of the
steps followed by TN patients along the
experimental design of the study. Note
that from the 42 TN patients who were
assessed to participate in this study, 12
were excluded before allocation owing to
exclusion criteria and 7 following Proto-
col II had to leave the study at day 7
owing to insufficient pain control.
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interval (CI) for each NNT value was obtained using
the free calculator at the site of the University of
Manchester www.phsim.man.ac.uk/nnt:
NNT ¼
1
50%VAS reductionGBPþROPpatients
Total number of GBPþROPpatients  50%VAS reductionGBPonly patientsTotal number of GBPonly patients
Evaluation of Patient Quality of Life—SIP
A secondary outcome measure of this study was
the evaluation of the Quality of Life of patients using
the SIP (‘‘Sickness Impact Proﬁle’’)32–34 adapted to the
Portuguese population (McIntyre and Arau´jo-Soares,
1999 and personal communication). SIP evaluates the
descriptive proﬁle of the patients in terms of impact of the
pathology analyzed upon speciﬁc day life behaviors. It is
constituted by 136 questions divided along 11 categories.
To analyze each patient in dimensions other than pain
intensity, patients were requested by the staﬀ to answer
the SIP at the beginning (day 0) and end (day 28) of
GBP+ROP and ROP protocols. We analyzed the answers
obtained at day 0 and day 28 in the following categories:
‘‘Domestic Work,’’ ‘‘Mobility,’’ ‘‘Communication,’’
‘‘Locomotion,’’ ‘‘Eating,’’ ‘‘Recreation-Pastimes,’’ ‘‘Mobi-
lity,’’ ‘‘Emotion,’’ ‘‘Social Interaction,’’ ‘‘Alertness,’’ and
‘‘Rest.’’ Additionally, the longitudinal evolution of the
SIP total score was also evaluated between the beginning
and end of each therapy. It should be noted that the score
obtained in each category of the SIP is inversely
proportional to the performing capacity of the patient.
Power of the Study
We previously determined that the number of
patients allocated to each protocol should be 12, as a
balance between the small incidence of TN patients in the
population and a suﬃcient number of patients to avoid
too small a sample. A total of 36 patients entered this
3 treatment parallel-designed randomized and blinded
study, GBP (Protocol I), ROP (Protocol II), and
GBP+ROP (Protocol III). In the context of 1-way
analysis of variance (ANOVA) (single factor experiments
allowing the comparison of more than 2 treatments),
Montgomery35 suggests an approach for determining the
sample size according to the interest of the experimenter,
bearing in mind that small eﬀects requires replication.
When the null hypothesis is rejected, the mean square of
treatment/mean square error statistic is a noncentral
F random variable (section 4.2 of Montgomery35). The
probability of type II error can be expressed as a function
of the diﬀerence of any 2 treatments (Appendix Chart V
of Montgomery28). In the present case, we have con-
sidered that a diﬀerence of 2 VAS units was the minimum
clinically relevant decrease in pain control measured by
the VAS score when comparing 2 treatments, as sustained
by others.26–28 For diﬀerent estimates of the standard
deviation (SD) and for diﬀerent number of patients,
power was determined. For estimates of the SD ranging
from 0.5 to 2 and number of patients ranging from 4 to
15, the power ranged from 0.9 to 0.97. The maximum
power was observed for a SD of 1.75 and a number of
patients of 12. In addition, we also determined the real
observed power at days 7 and 28 with the patients who
remained in the study, using SPSS 14.0 software for
Windows.
Statistics
Data are presented as media±SD along the several
variables under study. Tacking into account that at days
0, 7, and 28, data were obtained from patients of the 3
protocols tested, mean values were compared by 1-way
ANOVA followed by the Tukey post hoc test. Where the
homogeneity of variances was not observed, the non-
parametric test of Kruskal-Wallis was used. The w2 test
was applied to compare the sex distribution among the
3 groups. On the other hand, because only 2 protocols
were evaluated with the SIP at day 28 and at follow-ups
after the end of treatments (5 and 11mo), the mean values
from both Protocols I and III were compared by the
nonparametric Mann-Whitney test. The normal distribu-
tion of the results was veriﬁed using the Kolmogorov-
Smirnov test, whereas the equality of variances was
evaluated by the Levene test. The diﬀerences between
means from the diﬀerent protocols were considered
signiﬁcant when P<0.05. All calculations were carried
out using SPSS 14.0 for Windows.
RESULTS
Patient Baseline Characteristics
From the 42 TN patients assessed for eligibility, 36
patients were randomized (Fig. 1). Twelve assigned to
each treatment protocol. From those 12 patients assigned
to Protocol II (ROP), 7 had to abandon this therapy and
were excluded from the study because local analgesia of
trigger points with ROP each 7 days was insuﬃcient to
decrease pain below a VAS score of 6 for a long period.
These patients were excluded from the study and moved
to a conventional TN treatment after the ROP adminis-
tration at day 7. Figure 1 summarizes the ﬂow of patient
in this study. The analysis of the patients in the three
protocols showed no signiﬁcant diﬀerences (P=0.35 and
0.23, respectively) (Table 1) in demographic character-
istics including sex and age. In each protocol, no
diﬀerences were detected between patients with diﬀerent
TN trigger points owing to the rare incidence of this
pathology in the population and the number of patients
available for the study.
Effect of Different Protocols in Pain Control
No diﬀerences were found between patients from
Protocols I (GBP; VAS0=8.5±1.3), II (ROP; VAS0=
9.2±0.9), and III (GBP+ROP; VAS0=8.8±1.6)
(P=0.45) (Fig. 3) in pain intensity at the beginning of
the treatment (day 0). This result reinforces the homo-
geneity of the participants and the similarity between
patients allocated to the 3 protocols. After 7 days of each
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therapy (day 7), the 3 protocols reduced pain intensity
(ANOVA, P=0.03) but this reduction was signiﬁcantly
more pronounced in patients treated with GBP+ROP
(VAS7=4.5±1.6) compared with patients treated only
with GBP (VAS7=6.8±1.2; P=0.003) or ROP
(VAS7=6.3±1.8; P=0.025) (Fig. 3). No diﬀerences
were observed between GBP and ROP groups (P=0.71).
However, it should be noted that these ROP values
concerned only 5 of the 12 patients who have begun
Protocol II therapy. The other 7 patients had to drop the
study because VAS values reached 9.0±0.8 after 5 to 6
days with complete pain control and before rescue
medication that begun around day 6. When they arrived
the Pain unit at the seventh day under rescue medica-
tion (paracetamol), they were given the expected
ROP injection and moved immediately to conventional
AC drug therapy (carbamazepine or GBP). At the end
of the experimental period of treatment (day 28),
both Protocols I and III were eﬀective in controlling
pain in all 12 patients who have begun the treatment.
Although both protocols reduced pain intensity, this
eﬀect was more pronounced in patients treated with
GBP+ROP (VAS28=2.8±0.9) than in those treated
with GBP (VAS28=4.9±1.6; P<0.001). Interestingly, no
diﬀerences were observed between pain intensities of
GBP+ROP and the 5 ROP patients reaching the end of
the study (VAS28=3.4±0.6; P=0.56) (Fig. 3).
It is important to note that, in terms of time to
achieve a good improvement in pain, the drop in pain
intensity between days 0 and 7 was signiﬁcantly more
evident (P<0.001) in patients treated with GBP+ROP
(VASdif 7 0=4.3±1.6) than in patients treated only
with GBP (VASdif 7 0=1.8±1.0; P<0.01), with the
decrease being near signiﬁcance when compared with
the 5 ROP patients continuing the study (VASdif 7 0=
2.9±1.4; P=0.057). Additionally, if we consider the
decrease in pain intensity between days 0 and 28,
signiﬁcant diﬀerences were again observed between the
diﬀerent protocols (ANOVA, P=0.005). The decrease
in the GBP+ROP group reached 6.0±1.7 points in the
VAS scale (VASdif 28 0), which was signiﬁcantly more
expressive than the 3.6±1.8 points (VASdif 28 0)
decrease observed for GBP-treated patients (P=0.005)
(Fig. 3). Concerning the ROP-treated group, a signiﬁcant
decrease in pain intensity between days 0 and 28
(VAS28=3.4±0.6) was shown in the same 5 patients
at the end of the treatment, which reached 5.4±1.1
(VASdif 28 0) points (Fig. 3). No diﬀerences occurred in
total pain decrease between days 0 and 28 when compared
with GBP+ROP protocol (P=0.78).
The baseline number of daily crises of paroxysmal
sudden and intense pain was similar between patients of
the 3 protocols (ANOVA, P=0.36) [nepisodes=10.5±2.0
(GBP), 9.2±1.5 (ROP), and 9.8±1.5 (GBP+ROP)].
A clear decrease was observed after 28 days of treat-
ment (ANOVA, P<0.001), with patients treated with
FIGURE 2. Location of trigger points in 2 TN patients. Note
their location near the V3 (A), V2 (C), and V1 (D) branches
of the trigeminal nerve. B, The administration of ROP was
performed in the area pointed as a trigger point by the patient
in (A).
FIGURE 3. Effect of the 3 protocols (GBP, ROP, and GBP+ROP)
on the Pain Intensity of TN patients along the treatment. Note
the more intense and rapid reduction in pain scores following
GBP+ROP treatment. Additionally, a significant inferior pain
intensity was recorded by these patients at the end of the 28-
day period when compared with those treated only with GBP.
Note that patients evaluated in ROP group were 12 at day 0,
but only 5 at days 7 and 28. The number of patients included
in the mean (n) is present between brackets below the data
bars. For statistical significances, see Results section.
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GBP+ROP (nepisodes=2±1.0) showing a signiﬁcantly
lower number of pain crises than those treated only
with GBP (nepisodes=4.8±1.4; P<0.001) or ROP
(ncrises=6.8±0.8; P<0.001) (Fig. 4). It should be
recalled that at day 28, the number of patients in Protocol
II (ROP) was 5, but in this case the improvement was far
from being comparable with the GBP+ROP treatment.
Follow-up
Five months after the end of the 28 days of
treatment, the number of daily pain episodes
was signiﬁcantly lower (P<0.001) in the GBP+ROP
group (nepisodes=1.6±1.4) than in ROP group
(nepisodes=4.2±0.8; P=0.001), whereas in the GBP-
treated group the number of daily episodes has even raised
again (nepisodes=6.3±1.1; P<0.001) (Fig. 4). Eleven
months after the end of the treatment, the GBP+ROP
group of patients presented a statistically signiﬁcant lower
number of daily pain episodes (1±0.7) when compared
with both GBP (2.3±0.5; P<0.001) and ROP
(2.6±0.6; P<0.001) (Fig. 4). Note that only 5 patients
were evaluated in Protocol II (ROP) at these 2 time points
of follow-up. Again, the improvement in ROP patients
was inferior to that obtained by GBP+ROP patients.
GBP Daily Dose
At days 1 and 2, all GBP and GBP+ROP patients
took 100mg/d GBP. At day 7, GBP and GBP+ROP
patients were taken 200 or 300mg/d (mean=266.67mg/d).
Protocol III (GBP+ROP) resulted in a lower ﬁnal daily
dose of GBP (300mg/d in all patients) at the end of the
treatment (day 28) than in patients following Protocol I
(mean=525mg/d; minimum=300mg/d, maximum=
600mg/d) (Fig. 5). No GBP was administered to ROP-
treated patients.
NNT
When comparing the clinical beneﬁt obtained by
GBP+ROP and ROP protocols, the NNT for the
treatment associating GBP+ROP (Protocol III) over
the GBP treatment (Protocol I) was 1.71 (95% CI: 1.23-
3.67) at day 7 and 2.40 (95% CI: 1.46-8.49) at the end of
the therapy (day 28).
Power of the Study
The observed power of the present study was, for
0.90 for day 7 and 0.98 for day 28, when the alternative
hypothesis is set based on the observed values. For the
power of the study calculated before the experimental
period, see the Methods section.
Patient Quality of Life—SIP
For all categories studied, we analyzed only the
evolution of the Quality of Life scores obtained between
the beginning and the end of the treatment period (Table 2).
Accordingly, between the beginning (day 0) and the end
(day 28) of the treatment, it was observed that (Table 2)
(1) Protocol III patients showed a signiﬁcant improve-
ment in all SIP categories (P<0.05); (2) Protocol I
patients improved signiﬁcantly in 9 categories (P<0.05)
but failed to ameliorate in 2 categories, ‘‘Emotion’’ and
‘‘Alertness.’’
Patients treated with GBP+ROP showed a sig-
niﬁcant improvement in total SIP scores (Quality of Life)
after the period of treatment (day 0: GBP, 687.8±124.4;
GBP+ROP, 676.7±169.8; day 28: GBP, 543.2±60.7;
GBP+ROP, 476.3±60.6; P=0.038, Mann-Whitney,
U=36.00, z=  2.078; Fig. 6).
DISCUSSION
In the present study, we evaluated possible ther-
apeutic alternatives for TN patients who cannot be
treated with the main AC drug used for pain control
(CBZ). The clinical eﬃcacy of associating GBP and ROP
for TN treatment was determined by measuring pain
intensity, number of paroxysmal pain crises, NNT, and
Quality of Life provided to the patients. GBP mono-
therapy (Protocol I), ROP administration to trigger
points (Protocol II), and the proposed GBP+ROP
association (Protocol III) have all resulted in a signiﬁcant
reduction of the initial pain intensity and number of
crises. However, patients treated with the association of
GBP+ROP presented (1) a faster clinical improvement,
(2) a signiﬁcantly higher reduction of pain (VAS and
FIGURE 4. The number of daily episodes of paroxysmal pain
at the end of the treatment protocols and 5 and 11 months
later. It is evident a much more rapid and significant decrease
in pain episodes induced by the application of the associative
therapy GBP+ROP performed in Protocol III, especially in
comparison with GBP monotherapy. It should be noted that
following Protocol I (GBP only), the number of daily pain
episodes even enhanced from the end of the treatment to
5 months later. Additionally, patients evaluated in ROP group
were 12 at day 0, but only 5 at day 28 and after the follow-ups
5 and 11 months later. For statistical significances see Results
section.
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NNT scores), (3) an inferior daily dose of GBP, and
(4) a better Quality of Life than patients treated only
with GBP. On the other hand, it was clear that ROP alone
applied to TN trigger points (Protocol II) was suﬃcient
for a reliable satisfactory pain control in some but not
all patients.
Study Design and Methodologic Considerations
To perform this study, several aspects needed to be
addressed owing to the speciﬁc nature of TN pain. First,
the rationale was to increase the eﬃcacy of GBP13 in TN
to provide an improved alternative to patients where the
primary treatment with CBZ failed or cannot be applied;
thus, it was not an objective of the study to evaluate an
alternative to CBZ as a ﬁrst choice drug treatment for
TN pain. The possibility of associating GBP with a local
anesthetic in analgesic concentration occurred when pilot
studies of our group, using the administration of ROP as
a rescue analgesic in TN paroxysmal pain crises, showed
FIGURE 5. Longitudinal evolution of the daily dose of GBP
administered during treatment Protocols I and III. Prolonged
therapy with GBP+ROP needs significantly smaller doses of
GBP than GBP-only protocol at the end of the 28-day
treatment period.
TABLE 2. Scores of the Different Categories of the Quality of Life SIP Questionnaire Evaluated at the Beginning and End
of TN Therapeutical Protocols I and III
GBP (Protocol I) GBP+ROP (Protocol III)
Day 0 Day 30 Day 0 Day 30
SIP Categories Mean SD Mean SD Mean SD Mean SD
Locomotion 50.00 21.68 40.01 20.78 41.73 8.93 32.63 5.82
Wellbeing 81.11 28.49 34.28 3.76 52.55 26.82 33.20 2.85
Mobility 63.81 15.16 46.27 11.81 75.66 10.34 43.71 7.83
Domestic Work 71.95 21.78 55.56 17.58 68.61 22.15 53.61 8.58
Eating 40.85 17.75 25.35 4.39 53.38 24.86 29.95 12.50
Communication 53.15 18.30 38.32 5.45 65.49 19.32 42.19 8.67
Emotion 46.39 10.46 45.33 11.01 44.86 13.40 39.89 10.15
Recreation and Pastime 65.29 20.01 54.12 17.84 63.58 23.95 45.26 17.69
Social Interaction 80.09 25.47 74.63 24.45 86.02 19.14 66.11 23.59
Alertness 60.73 10.58 58.48 9.48 56.23 23.68 45.87 12.11
Rest 74.40 11.50 70.87 8.14 68.62 17.34 63.07 12.05
Total SIP Score 687.78 124.43 543.22 60.71 676.73 169.75 495.50 88.11
Italics indicate that there was a signiﬁcant improvement (P<0.05) in that category between days 0 and 30 of treatment.
Note that GBP+ROP-treated patients showed improvement in all categories analyzed, whereas GBP patients did not improve in 2 categories of the SIP.
FIGURE 6. Effect of Protocols I and III (GBP and GBP+ROP) on
the total SIP score of Quality of Life. Note that no differences
were observed at the beginning of the treatment (day 0)
between both patient groups. However, at the end of the
treatment (day 28), Protocol III induced a significant decrease
in the total SIP score, which indicates an improvement in the
Quality of Life of TN patients.
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a prolonged pain free state that largely overcame the
normal period of ROP local analgesia (72 h). Although
pain relief outlasting by days, weeks, or months, the short
duration of the pharmacologic action of local anesthetics
like ROP has been documented, a clear explanation for
this eﬀect is not currently available.21,22,36 It is possible
that the prolonged eﬀect is based not only on the
pharmacologic eﬀect of the drug but also on the physical
action of local administration of the analgesic solution by
clearing adhesions or inﬂammatory exudates from the
vicinity of the nerve.22 These mechanisms may explain the
improvement observed in a set of TN patients entered
into Protocol II (ROP only) treatment during this study.
In fact, trigeminal nerve block analgesia is a procedure
considered already as a TN treatment when pharmaco-
logic approaches have failed.22
Although other possibilities have been raised, we
decided that the third group of our study (in addition to
GBP and GBP+ROP) should be ROP treatment alone. A
second alternative could have been the administration of
saline injections upon TN trigger points in a group of GBP
patients; although protected by using GBP and acting as a
placebo for ROP, this group would not rule out the
physical eﬀect of administering a volume of liquid to each
trigger point. A third alternative, the possibility of having a
study branch with just saline administration to the trigger
points would be unethical and was not considered, because
no pain control would be achieved and, on the contrary, it
could induce paroxysmal pain crises. Thus, by using a third
group of patients treated with ROP monotherapy, we
evaluated the degree of pain control that can be achieved
just by the local analgesia plus the physical eﬀect of liquid
administration to trigger points.
The frequency and number of ROP injections
applied to TN patients followed the guidelines for the
practice of interventional techniques described by Man-
chikanti et al.22 It is advisable that in the stabilization
phase, a patient should receive an injection at intervals
not smaller than 1 week, which was the period chose to
mediate between each ROP administration. The follow-
up evaluation of patients treated with Protocols I and III,
it was performed by phone interview; consequently, while
the determination of the number of pain crises could be
assessed 6 and 12 months after the beginning of the
treatment, the pain intensity measured in a VAS scale was
obviously not possible to perform.
Clinical Significance of the GBP+ROP
Association
A 2-point decrease in the mean VAS scale (0 to 10
scale) has been considered the minimum clinical relevant
diﬀerence in pain intensity when comparing the eﬀect of 2
treatments.26–28 Taking into account that GBP, ROP, and
GBP+ROP treatments decreased pain intensity between
3.4 and 6.0 VAS points, all protocols were clinically
eﬀective in reducing pain after a 1-month therapy. When
comparing with GBP protocol, it is relevant to note that
GBP+ROP was not only more eﬃcient in reducing pain
intensity at the end of the treatment, but was the only
protocol being clinically eﬀective in reducing pain after
7 days of treatment. This suggests a potentiation or
synergism between the AC and local analgesic eﬀects when
associated in the same protocol. Curiously, ROP admin-
istration alone resulted in a pain decrease at the end of 28-
day treatment about as signiﬁcant as the GBP+ROP
association, but the follow-up evaluation was not so
eﬃcient. Although a careful systematic administration of
ROP to TN trigger points has been performed in patients
following Protocols II and III, further studies are needed
to determine the causes for the great variability and
unpredictability of pain control obtained in patients
submitted only to local analgesic block.
GBP Dose and Quality of Life
TN treatment with titrated GBP was adapted from
other studies16 and is used in several pain units in
Portugal. It started with a 100-mg daily administration
that is gradually increased by 100 to 300mg each 3 to 5
days until patients refer a satisfactory pain relief
(VAS<6) or intolerable side eﬀects16 (but see, initial
dose 300 to 900mg/d9,10,37). Clinically eﬀective GBP
doses given monotherapeutically are usually placed
between 900 and 1200mg/d but may reach concentrations
as high as 3600mg/d.16,37,38 To evaluate the best GBP
dose to be administered to each patient, the GBP dose in
our study started at 100mg/d in all protocols. At the end
of the treatment (day 28), the mean GBP daily adminis-
tration in patients treated with GBP+ROP was 300mg/d,
just a little higher that the dose at the seventh day. On the
contrary, patients treated with GBP monotherapy needed
signiﬁcantly higher doses of GBP (525mg/d) with the
mean dose on day 28 being the double of that recorded at
day 7. These data show that the clinical result of NT
treatment with GBP+ROP is superior to GBP mono-
therapy, because the low dose of GBP needed along
Protocol III did not result in a single patient showing the
usual side eﬀects associated with GBP, sedation, ataxias,
and dizziness.39 The possibility of GBP subtherapeutic
treatment was excluded, as shown by the signiﬁcant pain
decrease and improvement of Quality of Life.
The evaluation of Quality of Life in TN patients
revealed a clear beneﬁcial eﬀect in 9 of the 11 categories
analyzed with SIP32,33 in patients treated with GBP+
ROP, whereas GBP-only treated patients showed
improvement in 9 categories. Thus, the general functional
well-being of TN patients improved signiﬁcantly in more
SIP categories following the GBP+ROP protocol.
Accordingly, the longitudinal analysis of the SIP total
score showed a signiﬁcant improvement in the functional
status of GBP+ROP patients.
Potential Mechanisms Mediating GBP+ROP
Therapeutic Association
To the best of our knowledge, no studies have
evaluated the clinical eﬀect of associating an AC with
another drug therapy for treating TN.1,2,37 This fact is
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intriguing because pain reduction with ACs seems to
decrease pain only about 30% owing to incomplete
eﬃciency, adverse side eﬀects, or both.40–42 Even for
treating neuropathic pain in general, only a recent study
associating GBP and morphine applied to patients with
diabetic neuropathy and postherpetic neuralgia is worth
mentioning owing to the signiﬁcant reduction of daily
pain intensity measured by the VAS scale and McGill
Pain Questionnaire.40
Complementary mechanisms associated with the
local analgesic action of ROP and GBP may be at
the basis for the strong pain reduction resulting from the
association of both therapies in Protocol III. Low-dose
ROP has an analgesic action similar to CBZ, because
both drugs act on voltage-gated sodium channels,11,43,44
reducing the membrane potential oscillations and mem-
brane excitability associated to neuropathic pain45 but
not blocking nerve conduction.15,44 GBP also suppresses
ectopic aﬀerent discharge activity generated by injured
peripheral ﬁbers,10,46 without blocking nerve conduc-
tion.15,40 The analgesic action of GBP is not based on
blocking sodium channels along nerve ﬁbers47,48 but on
voltage-gated calcium channels containing the a2d sub-
unit.49,50 Calcium channels are essential for modulation
of cell-membrane excitability and thus are implicated in
neuropathic pain,51 with the expression of the a2d subunit
being increased in some neuropathic models.52 These
channels are also essential for the release of central
neurotransmitters from axonal terminal boutons to the
synaptic gap51 and pregabalin (a close structural relative
of GBP) binding to the a2d subunit reduces their
presynaptic liberation.53 The importance of this eﬀect
in GBP action is not known as ACs that act synaptically
(eg, barbiturates) are largely ineﬀective as analgesics.15
According to the ‘‘ignition hypothesis’’ of TN,15,54,55 pain
paroxysms begin with discharges in a small set of
trigeminal primary aﬀerents resulting from spontaneous
activation or after cutaneous trigger point stimulation.
Crossed-afterdischarge then excites nonstimulated neigh-
bor ﬁbers through a ‘‘windup’’ mechanism that self-
sustains ﬁber activity beyond the original focal ﬁber
discharge. It should also be pointed that a central eﬀect of
ROP may exist owing to some degree of systemic
circulation.15 Thus, it is possible that the therapeutic
value of the present GBP+ROP association may result
from the synergistic/additive control of (1) ﬁber depolar-
ization at trigger points (by ROP), (2) crossed-
afterdischarge of passive neighboring neurons at the
trigeminal ganglion (by GBP and ROP), and (3) central
neurotransmitter release from primary aﬀerents (GBP).
Limitations of the Study
There are 4 main limitations to the present study.
First, the generalization of the ﬁndings to all patients who
do not tolerate drug therapy after CBZ should be made
with caution because no comparisons were made with
other ACs that can be alternative to the main treatment.
The exclusion criteria were extensive and 14% of TN
patients arriving to the Pain Unit were withdrawn from
the study, which indicates that the data need to be
conﬁrmed in a less homogenous population. Second,
although all eﬀort has been made to avoid patients
meeting with each another within and between protocols
and all patients from the 3 protocols have been evaluated
by the hospital staﬀ, it was not possible to blind patients
to therapeutic group (ROP injection vs. no injection).
Thus, the study was blinded only to the research staﬀ.
Third, it was only possible to perform the follow-up by
phone interview, which precluded the possibility of
evaluating the Quality of Live in patients since the SIP
has 136 questions. Consequently, patients’ VAS pain was
used as a surrogate measure. Patients were also trained to
count their number of daily pain periods and this measure
was also obtained at the follow-up. Finally, although
the therapeutic eﬀect on the number of crises was still
signiﬁcantly diﬀerent after a year of treatment with
GBP+ROP and ROP, the follow-up period may not
have been suﬃcient to determine the long-term eﬀect of
the proposed treatment.
CONCLUSIONS
GBP is already the ﬁrst choice drug therapy for all
types of neuropathic chronic pain in several international
pain control centers, owing to the facility of monitoring,
relatively low incidence of adverse side eﬀects, lack of
interaction with other drugs acting on the nervous system,
and evident perception of its eﬃcacy.10,11,56,57 However,
concerning TN, CBZ has been the most widely used drug
therapy, with signiﬁcant results on pain relief obtained in
large scale placebo studies.5,8 On the other hand,
whenever CBZ fails to control TN pain, GBP is an
alternative for reducing its intensity.13,14 The present
study indicates that the association of oral GBP and
peripheral analgesic block with low-dose ROP results in a
clinical pain control of TN with a rapidity, a decrease in
pain intensity and a long-term action that is superior to
GBP monotherapy. This is reinforced by complete lack
of adverse side eﬀects and the global improvement of
the functional Life Quality of TN patients submitted
to GBP+ROP therapeutic association. However, large-
scale GBP studies are needed to place more accurately
GBP in the spectrum of drugs that can be used in TN
pain control.
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